Is Avonib available in China?

Ivosidenib is a targeted drug mainly used to treat specific types of acute myeloid leukemia (AML), especially those carrying IDH1 gene mutations. This mutation causes abnormal cell metabolism and promotes the growth of cancer cells. Ivonib inhibits the activity of IDH1 mutant enzyme and reduces the production of abnormal metabolites, thereby restoring the normal cell differentiation process and inhibiting the proliferation of cancer cells. As a targeted drug specifically targeting IDH1 mutations, ivonib provides a new treatment option for patients with refractory or relapsed AML.

In China, ivonib is already on the market, but because it has not yet been included in medical insurance, the price is relatively high. When patients purchase Avonib in the country, they usually have to pay around 30,000 to 40,000 yuan. This price represents a heavy financial burden for many patients, so patients are advised to consult their local hospital pharmacy for specific pricing and availability before purchasing.

In comparison, generic versions abroad, especially in Laos, are relatively cheap. The price of generic drugs in Laos is usually around 6,000 to 7,000 yuan, which is significantly lower than the price of domestic original drugs. Despite their low price, the ingredients of these generic drugs are basically the same as the original drugs, making Lao generic drugs an affordable option for many patients.

When choosing a drug, patients should consider the price, quality of the drug and the legality of the supply channel. For qualified patients, it is recommended to choose a treatment plan suitable for their own conditions under the guidance of a doctor. If you are considering purchasing generic medicines, you should make sure to do so through legal channels to ensure the quality and safety of the medicines. At the same time, patients should also pay attention to the latest medical insurance policies to understand whether it is possible to include ivonib in the scope of medical insurance in the future, thereby reducing the financial burden.